Noteworthy

XOFIGO (radium Ra 223 dichloride) Approved for New Treatment

TARCEVA (erlotinib) Now Approved for NSCLC

ICLUSIG (ponatinib) Now Approved

Stivarga (regorafenib) approved for GIST

AVASTIN (bevacizumab)

Now approved for a new indication

NEW Drugs AND EXPANDED COVERAGES

Below are postings for new drugs and indications you should be aware of. Please refer to the links below for announcements and details.

ABRAXANE (for injectable suspension) NSCLC 11/01/12

ALIMTA (pemetrexed for injection) - Non-Small Cell Lung 11/16/12

AVASTIN (bevacizumab) New Indication Colon Cancer (02/05/13)

ICLUSIG (ponatinib) - CML (4/11/2013)

KADCYLA (ado-trastuzumb emtansine) HER2-positive metastatic breast cancer (02/27/13)

POMALYST (pomalidomide) capsules Multiple Myeloma (02/27/13)

STIVARGA (regorafenib) GIST 03/04/13

TARCEVA (erlotinib) NSCLC 5/21/13

XOFIGO (radium Ra 223 dichloride) Prostate 5/21/13

ZYTIGA (abiraterone acetate) Expanded Indication Prostate Cancer (12/10/12)